向葡萄糖胺合成酶:用于溶解体疾病的创新药物重定位策略
Giorgia Canini1, Elena Mazzinelli1, Giuseppina Nocca1,2
1Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy.
International journal of molecular sciences
|March 13, 2025
概括
药物重新定位发现Dapagliflozin是一种有前途的新疗法,用于治疗罕见的遗传性疾病 - - 脊髓脂症. 这种葡萄糖胺合成酶抑制剂可能为当前疗法提供更安全的替代方案.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 斯芬戈脂症是罕见的溶酶体储存疾病,治疗选择有限.
- 米格鲁斯塔特是一种现有疗法,但具有显著的不良影响.
- 药物重新定位是一种可行的策略,用于识别罕见疾病的新疗法.
研究的目的:
- 通过药物重定位来识别新型的葡萄糖胺合成酶 (GCS) 抑制剂用于脂类酶.
- 评估已批准的药物的治疗潜力,作为 Miglustat 的替代品.
- 评估已识别的候选药物的疗效和安全性.
主要方法:
- 使用分子对接,分子动力学和元动力学对批准的药物库进行计算选.
- 在实验室验证有希望的GCS抑制剂候选者.
- 对针对Miglustat. 的已识别药物的比较分析.
主要成果:
- 计算查发现了几种潜在的GCS抑制剂.
- 达帕格利弗洛辛 (Dapagliflozin) 成为最有前途的候选药物.
- 实验验证证证实了Dapagliflozin的疗效和与Miglustat相比可能有利的副作用概况.
结论:
- 药物重新定位,结合计算和实验方法,对于罕见疾病研究是有效的.
- 达帕格利弗洛辛显示出作为治疗斯芬戈脂症的治疗剂的潜力.
- 需要进行进一步的临床前和临床研究,以评估达帕格利弗洛辛在脂类瘤治疗中的作用.
相关概念视频
Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
Oligosaccharide Assembly
2.7K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
2.7K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K


